• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Intersect ENT wins preliminary CMS reimbursement code

April 30, 2019 By Nancy Crotti

Intersect ENT updatedShares in Intersect ENT (NSDQ:XENT) got a boost yesterday on news that the Centers for Medicare and Medicaid Services (CMS) had assigned the company’s Sinuva corticosteroid-eluting sinus implant a preliminary J-code.

Intersect ENT stock, which had been bumping along just under $30 per share last week, jumped to $33.13 per share at Monday’s market open, then dipped slightly, opening today at $31.96.

Analysts at SVBLeerink expect Sinuva to gain a permanent J-code in January 2020, and believe that should help the device gain private-payer reimbursement over the coming years. They also said expect Sinuva to generate $10 million in revenue this year, and approximately $28 million in 2020.

“We don’t expect much of a tangible SINUVA (revenue) impact in the very near-term (i.e. 2019), and we’d note that mgmt. has previously indicated that its 2019 (revenue) outlook is not contingent upon receiving a J-Code,” they added.

Intersect ENT (Menlo Park, Calif.) is expected to issue new earnings guidance for 2019 in its first-quarter earnings report on Monday, May 6, the analysts wrote. The company declined to comment on the CMS decision.

Sinuva is designed to deliver an anti-inflammatory steroid (mometasone furoate) directly to the site of nasal polyps for up to 90 days. Made of bioabsorbable polymers designed to soften over time, the implant softens and polyps decrease, according to  Intersect ENT. The device can be implanted a doctor’s office under local or topical anesthesia and is intended for adults who have had previous sinus surgery.

Intersect ENT won FDA approval for Sinuva in December 2017 and launched in the U.S. in April 2018.

Filed Under: Drug-Device Combinations, Featured, Implants, Uncategorized Tagged With: Centers for Medicare and Medicaid Services (CMS), Intersect ENT Inc., SVB Leerink

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS